Eli Lilly warned Monday that some Medicare beneficiaries could pay more than the widely cited $50 monthly cap for weight-loss drugs under a new federal coverage model, cautioning that cost-sharing may vary across a limited number of basic Medicare Part D plans.
The company said in a press release that most participating plans are expected to honor the $50 out-of-pocket limit, but a small subset may not fully comply with the cap. The issue stems from a voluntary program launched by the Centers for Medicare and Medicaid Services that aims to expand coverage for GLP-1 drugs used to treat obesity and diabetes. Under the model, CMS negotiates standardized coverage terms and net prices with drugmakers, with the goal of lowering patient costs while pairing drug coverage with lifestyle and behavioral support.
Lilly’s injectable drugs Zepbound and Mounjaro will become available through participating Medicare Part D plans beginning Jan. 1, 2027, marking a significant shift in how weight-loss drugs are covered under the federal program. The company said it plans to actively educate patients and physicians about plan options, including programs designed to smooth out-of-pocket costs over the course of the year.
Current GLP-1 Costs
GLP-1 weight-loss drugs such as Wegovy, Zepbound and Mounjaro typically carry list prices that exceed $1,000 per month for patients paying out of pocket, though actual costs can vary widely depending on insurance coverage, discounts and manufacturer programs. Without coverage, many patients face monthly bills in the high hundreds to more than a thousand dollars, while insured patients may pay significantly less through copays or negotiated rates, particularly as Medicare and Medicaid coverage expands under new federal agreements.
Timeline for Effects
Weight-loss drugs in the GLP-1 class often begin affecting appetite within the first few weeks of treatment, though meaningful weight loss typically develops over several months as doses are gradually increased. Medical experts say patients may notice reduced hunger early on, but the most significant and sustained weight changes generally occur after consistent use over three to five months, with results varying based on the medication, dosage and individual response.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.newsweek.com/medicare-update-glp-weight-loss-drugs-mounjaro-zepbound-11648673